Stimulation of endothelial non-neuronal muscarinic receptor attenuates the progression of atherosclerosis via inhibiting endothelial cells activation. 2014

Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang

OBJECTIVE To investigate the effects of non-neuronal muscarinic receptors (NNMR) stimulation on atherosclerosis and endothelial cells activation. METHODS Atherosclerosis model was established in ApoE-/- mice by a high fat diet for 7 weeks. During the experimental periods, animals were received a low (7 mg/kg/d) or a high (21 mg/kg/d) dose of arecoline by gavage. At the termination of the treatments, serum total cholesterol and NO levels were measured, and the aorta morphology was analyzed by hematoxylin and eosin staining. The gene expression of monocyte chemoattractant protein-1 (MCP-1) and adhesion molecules in the thoracic aortas was determined by RT-PCR, and the MCP-1 protein expression and NF-κB activity were detected by Western blot analysis. NO production, MCP-1 secretion in cultured rat aortic endothelial cells (RAECs), and monocyte-endothelium adhesion assay were also performed after arecoline treatments. RESULTS Arecoline efficiently decreased atherosclerotic plaque areas, increased serum nitric oxide (NO) content, suppressed the mRNA and protein expression of MCP-1, and modulated the IκB-α degradation and P65 phosphorylation in the aortae of ApoE-/- mice. Furthermore, arecoline promoted NO production and suppressed MCP-1 secretion in cultured RAECs after ox-LDL exposure, and either atropine or NG-nitro-L-arginine methylester could abrogate these effects. Arecoline also significantly inhibited the adherence of U937 monocytes to the ox-LDL injured human umbilical vein endothelial cells, which could be abolished by atropine. CONCLUSIONS Our results indicate that arecoline attenuates the progression of atherosclerosis and inhibits endothelial cells activation and adherence by stimulating endothelial NNMR. These effects, at least in part, are due to its modulation on NF-κB activity.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072000 NF-KappaB Inhibitor alpha An I-kappa B protein that inhibits the activity of dimeric NF-KAPPA B P50-REL complexes, sequesters transcription factor NF-kappaB as an inactive complex in the cytoplasm; and prevents NF-kappaB nuclear translocation and DNA binding. I Kappa B-alpha Protein,IKappaB-alpha,IKappaBalpha,Major Histocompatibility Complex Enhancer-Binding Protein MAD3,p40 Protein (IKappaB-alpha),I Kappa B alpha Protein,IKappaB alpha,Inhibitor alpha, NF-KappaB,Major Histocompatibility Complex Enhancer Binding Protein MAD3,NF KappaB Inhibitor alpha,alpha, NF-KappaB Inhibitor
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001011 Aorta The main trunk of the systemic arteries. Aortas

Related Publications

Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
November 2013, Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
November 2020, Aging,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
January 2013, Life sciences,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
January 2016, PloS one,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
January 2020, Mediators of inflammation,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
July 2022, Genes,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
May 2012, Cancer biology & therapy,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
January 2012, Handbook of experimental pharmacology,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
January 2015, PloS one,
Jing-Hong Zhou, and Zhi-Yuan Pan, and Yan-Fang Zhang, and Wen-Yu Cui, and Chao-Liang Long, and Hai Wang
April 2013, Genes,
Copied contents to your clipboard!